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WU polyomavirus is a recently described polyomavi-
rus found in patients with respiratory infections. Of 2,637 
respiratory samples tested in St. Louis, Missouri, 2.7% were 
positive for WU polyomavirus by PCR, and 71% were coin-
fected with other respiratory viruses. Persistent human in-
fection with WU polyomavirus is described.
A
n initial report described the identiﬁ  cation of WU poly-
omavirus in 6 (0.7%) of 890 respiratory tract samples 
collected in St. Louis, Missouri, USA, and in 37 (3.0%) 
of 1,245 respiratory tract specimens tested from Brisbane, 
Queensland, Australia (1). The goal of our study was to ex-
tend these initial ﬁ  ndings by determining the prevalence of 
WU polyomavirus in a larger patient cohort in St. Louis.
The Study
We tested 2,637 nasopharyngeal swabs or nasal wash-
es (from patients 1 day to 88 years of age) submitted to 
the virology laboratory at St. Louis Children’s Hospital for 
routine respiratory virus detection from July 2003 through 
June 2004. Of these samples, 2,263 were from children <4 
years of age (including 419 newborns) and 374 were from 
children >4 years of age. The specimens were extracted 
with the automated Roche MagNA Pure LC extractor and 
MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche 
Diagnostics, Indianapolis, IN, USA).
For real-time PCR, ampliﬁ  cation primers WU-TAB02-
F 5′- TGTTGCATCCATTTGTTACATTCAT-3′ and WU-
TAB03-R 5′-GAAAGAACTGTTAGACAAATATATAG-
GCCTTA-3′ and the minor groove binder probe 
WU-TAB04-pro 5′-6FAMATGTCAGCAAATTCMGB-
NFQ-3′ were used with a commercially available universal 
TaqMan real-time PCR master mix and ABI 7500 Real-
Time Thermocycler (Applied Biosystems, Foster City, 
CA, USA). All WU polyomavirus–positive specimens 
were screened for 17 additional viruses (inﬂ  uenza A and B; 
RSV A and B; PIV 1–4; human metapneumovirus; adeno-
virus subgroups B, C, and E; rhinovirus; and coronaviruses 
OC43, 229E, and NL63) by using the EraGen MultiCode-
PLx respiratory virus panel as described previously (1).
Each clinical specimen was assigned a code. Collection 
of clinical data was approved by the Washington University 
Human Research Protection Ofﬁ  ce. Pertinent demograph-
ic, historical, and clinical information, when available, was 
collected by using a standard collection form. Statistical 
signiﬁ  cance was determined by using 2-tailed Fisher exact 
χ2 tests with Epi Info software version 3.4 (Centers for Dis-
ease Control and Prevention, Atlanta, GA, USA )
Seventy (2.7%) of the 2,637 tested specimens were 
positive for WU polyomavirus; 71% of the positive sam-
ples were also positive for >1 other respiratory virus. Of the 
70 positive samples, 5 were omitted from analysis because 
of chart unavailability. The remaining 65 samples were col-
lected from 60 individual patients (5 specimens were serial 
samples associated with distinct clinical syndromes in 2 
immunocompromised patients).
Of the 60 WU-positive patients, 31 (52%) were fe-
male. The ethnic breakdown was as follows: 50% African-
American, 47% Caucasian, 3% other. Positive specimens 
were noted for patients 1 day to 15 years of age (online 
Appendix Table, available from www.cdc.gov/EID/con-
tent/13/12/1936-appT.htm). The highest and lowest rates 
of infection are displayed in the Figure, panel A.
Patients positive for WU polyomavirus were detected 
throughout the year. A small peak was observed in July 
2003, and a second small peak was observed in April and 
May 2004 (Figure, panel B). WU polyomavirus was the 
only virus detected in a 1-day-old full-term infant deliv-
ered by cesarean section who had been transferred to St. 
Louis Children’s Hospital with respiratory distress requir-
ing intubation. He was afebrile with lung opacities on chest 
radiograph. Patent ductus arteriosus and pulmonary hyper-
tension were eventually diagnosed.
The 3 oldest patients positive for WU polyomavirus 
in this cohort were immunosuppressed. They included a 
12-year-old with Evans syndrome and a 15-year-old with 
severe combined immunodeﬁ  ciency syndrome (both post–
bone marrow transplant) and a 14-year-old with end-stage 
renal disease and asthma.
The most common clinical ﬁ   ndings in the patients 
with WU polyomavirus are listed in the Table. The most 
frequent diagnoses were pneumonia (31%) (although 40% 
had positive bacterial cultures), bronchiolitis (25%), and 
upper respiratory tract infections (15%). We also compared 
all the measured parameters from the patients who were in-
fected with WU alone to the patients who were co-infected 
with other viruses. In most cases, no statistically signiﬁ  -
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cant differences occurred between the co-infected and WU 
polyomavirus–only patients, except that more co-infected 
patients than WU polyomavirus–only patients had rhinor-
rhea (23/47 vs. 2/18; p = 0.005) and upper respiratory tract 
symptoms (30/47 vs. 6/18; p = 0.049). In addition, signiﬁ  -
cantly more children with co-infection than with only WU 
polyomavirus had prior daycare exposure (18/45 vs. 1/15; 
p = 0.02).
The cohort of 2,637 samples included several sets of 
sequential samples taken from the same patient during 
the course of prolonged illness. In 2 patients, sequential 
samples obtained over a span of 6–8 weeks were positive 
for WU polyomavirus. The ﬁ  rst patient was a 4-year-old 
girl with hemophagocytic lymphohistiocytosis, who had 4 
distinct respiratory specimens that tested positive during a 
2-month period. Her ﬁ  rst positive specimen was obtained 
while she was asymptomatic during admission for a bone 
marrow transplant in September 2003. A second sample 
was obtained during a clinic visit for nasal congestion and 
cough in November 2003. Her third sample (also positive 
for coronavirus OC43) was obtained during an admission 
5 days later for pneumonia. Finally, a fourth sample (nega-
tive for the previously detected coronavirus OC43) was 
taken 7 days later during the same admission after an epi-
sode of apnea.
The second patient was a 16-month-old child with bili-
ary atresia admitted for a liver transplant in September 2003. 
He had 3 positive samples during a 6-week period. An ini-
tial sample taken on admission was negative for WU poly-
omavirus. Six weeks after transplant, fever and shortness of 
breath requiring intubation developed. A sample taken then 
was positive for both WU polyomavirus and adenovirus. 
Four weeks later, worsening shortness of breath and fever 
developed. His blood cultures were now also positive for 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 12, December 2007  1937 
Table. Clinical parameters in episodes of WU polyomavirus 
infection
Symptoms and physical examination findings (n = 65) %
Symptoms
 Cough 57
   Upper respiratory tract symptoms 55
   Rhonchi/crackles/coarse breath sounds 46
   Shortness of breath or increased work of breathing 42
   Wheezing 40
   Rhinorrhea 38
   Retractions 37
   Decreased oral intake 34
   Vomiting 32
   Diarrhea 18
   Stridor 6
   Rash 6
   Apnea 5
Signs
   Tachypnea* (n = 57) 79
   Hypoxia† (n = 55) 47
   Fever‡ (n = 63) 41
   Bandemia (n = 42) 40
   Leukocytosis§ (n = 42) 31
   Leukopenia¶ (n = 42) 10
Radiographic or computed tomographic findings (n = 50)
   Infiltrate or consolidation 72
   Hyperinflation 14
   Peribronchial cuffing 12
   Effusions 6
Treatment
   Antimicrobial agents (n = 65)  58
   Bronchodilators (n = 65) 38
   Steroids (n = 65) 37
   Oxygen (n = 65)  25
   Intubation (n = 63) 11
   Intensive care (n = 63) 19
Risk factors
   Daycare 32
   Sick contacts 25
Medical history
  Asthma (n = 60) 37
*Defined per National Institutes of Health clinical center guidelines. 
†SaO2 <95% or PaO2 >80%. 
‡Temperature >38°C.
§Leukocyte count >15,000/mm
3.
¶Leukocyte count <4,000/mm
3.
Figure. A) Percentage of samples positive for WU polyomavirus by 
age group. B) Percentage of samples positive for WU polyomavirus 
by month.DISPATCHES
Klebsiella and Enterobacter spp., and his third respiratory 
sample demonstrated both WU polyomavirus and rhinovi-
rus. Two weeks later, fever, hypoxia, and increasing secre-
tions developed, with his fourth sample positive only for 
WU polyomavirus. Followup samples obtained 3 months 
later for each patient indicated clearance of WU virus.
Conclusions
Patients infected with WU polyomavirus in this cohort 
were primarily hospitalized with pneumonia, bronchiolitis, 
and upper respiratory tract infections. One new observa-
tion is that multiple respiratory specimens sampled from 
the same patient over 6–8 weeks were positive for WU 
polyomavirus, which suggests that WU polyomavirus may 
persistently infect humans. Both patients were immuno-
compromised, although they were able to clear infections 
with other viruses (coronavirus OC43, rhinovirus, adeno-
virus), which suggests that the continued detection of WU 
polyomavirus was not due to a completely incapacitated 
immune system. Sequence analysis of a 250-bp fragment 
of the VP2 gene of WU polyomavirus ampliﬁ  ed from mul-
tiple samples from the 2 patients showed no sequence poly-
morphisms between the initial and later samples (data not 
shown). As some sequence variation has previously been 
reported in this locus (1), these data are consistent with the 
model of persistent infection. The detection of WU poly-
omavirus in the respiratory secretions of a 1-day-old infant 
suggests that vertical transmission of WU polyomavirus 
from mother to fetus may occur, although further studies 
are needed to verify this suggestion.
In conclusion, WU polyomavirus was detected in 2.7% 
of patients with respiratory tract infections. A high percent-
age of coinfection with other respiratory viruses was de-
tected, complicating interpretation of the clinical ﬁ  ndings. 
However, WU polyomavirus was the sole virus detected in 
20 specimens from patients with respiratory illness, which 
suggests that it may be a respiratory pathogen. Finally, the 
observed persistence of this virus suggests analogy to BK 
and JC viruses in this regard (2).
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